Side Effects of Antipsychotic Medications

Completed

Conditions studied: Insulin Resistance, Metabolic Syndrome X, Schizophrenia and Disorders With Psychotic Features, Mood Disorders, Psychotic Disorders

In brief

Medications like olanzapine have been associated with the development of weight gain and diabetes in some patients. It is not known if the increased risk of developing diabetes is a direct effect on insulin or simply related to weight gain. We hope to learn in this study whether or not olanzapine directly slows down insulin secretion from the pancreas, thereby increasing the risk of developing diabetes.

Key facts

Study ID

NCT00363181

Run by

Stanford University

People needed

76

Starts

2006-04-01

Expected to finish

2011-12-01

Last updated by the study team

2021-03-22

Who can join

Age: 30 and older, up to 66. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants 30-66 years of age
• Body mass index (BMI) >25 < 35 kg/m2.
• Fasting plasma glucose concentration < 126 mg/dL
• Stable on one of the following psychiatric medication: Olanzapine (Zyprexa®), Ziprasidone (Geodon®), Aripiprazole (Abilify®), or Risperidone (Risperdal®)
• Stable on psychiatric medication for at least 3 months

You may not qualify if…

• Medications that directly affect insulin-mediated glucose disposal
• Intense suicidal impulses/intent
• Alcohol or substance abuse for 3 months.
• Major medical problems, i.e., clinically unstable medical disorder or condition; cardiovascular, hepatic, renal, gastrointestinal, pulmonary, endocrine or other systemic disease that would, in the investigator's clinical judgment interfere with the endocrine measures obtained in this study.

Where it is running

• VA Palo Alto Health Care System — Palo Alto, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.